L'intérêt à découvert pour Kymera Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Kymera Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Kymera Therapeutics (NASDAQ:KYMR) Stock, Rapport sur les intérêts à découvert

Kymera Therapeutics

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Kymera Therapeutics Inc

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is gearing up for an ambitious global expansion, setting its sights on significantly increasing its production capacity.
The company plans to initiate construction on several new semiconductor fabrication plants worldwide by 2025, with more than ten facilities either newly built or under construction, Economic Daily News <a target="_blank" href="https://udn.com/news/story/7240/8366464" rel="noreferrer noopener">reports</a>.
The contract chipmaker&#8217;s substantial capital investment will likely climb to unparalleled levels in 2025, with legal forecasts suggesting expenditures could range from $34 billion to $38 billion, pushing the company&#8217;s capital outlay to record highs.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/11/42008569/salesforce-loses-ai-chief-amid-major-push-for-autonomous-agents" rel="noreferrer noopener">Salesforce Loses AI Chief Amid Major Push for Autonomous Agents</a>
Industry insiders told Economic Daily News this surge in capital spending is a direct response to the growing demand for advanced semiconductor manufacturing processes, including the ramp-up of 2-nanometer technology.
Taiwan Semiconductor&#8217;s ongoing expansion involves multiple projects within Taiwan, including significant developments in Hsinchu and Kaohsiung.
According to the report, these locations will likely serve as core production bases for advanced 2-nanometer chips. Four fabrication plants, focusing on cutting-edge wafer manufacturing, are planned across these two regions.
Additionally, advanced packaging facilities are under development, incorporating the latest CoWoS (Chip-on-Wafer-on-Substrate) and SoIC (System-on-Integrated-Chips) technologies.
On the international front, Taiwan Semiconductor is moving forward with its plans for new plants in key overseas markets.
The company has confirmed that construction of its second factory in Japan&#8217;s Kumamoto region will commence in early 2025, targeting mass production by 2027.
In the United States, Taiwan Semiconductor is advancing with the buildout of a second wafer fab in Arizona, while a specialized process facility in Dresden, Germany, is also making headway.
Industry data told Economic Daily News that Taiwan Semiconductor&#8217;s aggressive growth trajectory will lead to an average of five new factories annually between 2022 and 2023. In 2024, this pace is expected to accelerate, with the company planning to build seven new facilities, including three advanced wafer fabs and two state-of-the-art packaging plants, alongside two overseas factories.
By 2025, Taiwan Semiconductor aims to exceed ten simultaneous projects globally—a first for the semiconductor sector and a significant boost to the company&#8217;s output capacity.
Taiwan Semiconductor will receive up to <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" rel="noreferrer noopener">$6.6 billion in U.S. funding</a> and $5 billion in proposed loans to develop advanced semiconductor plants in Arizona, strengthening local chip production.
The contract chipmaker&#8217;s Arizona facilities will likely begin operations in early 2025, producing chips for future technologies like 5G/6G networks and AI applications.
The chip manufacturer has accelerated its use of extreme ultraviolet (EUV) lithography systems, a crucial tool in semiconductor production, despite their high costs. Each EUV system exceeds $100 million, ranking among the priciest equipment in the industry.
Analysts estimate that Taiwan Semiconductor has expanded its EUV capacity significantly, growing its global share of EUV installations from 50% in 2020 to 56% in 2023.
Taiwan Semiconductor stock surged over 83% year-to-date.
Price Action: TSM stock traded lower by 1.11% to $183.95 premarket at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42005094/lenovo-q2-earnings-cloud-momentum-ai-pcs-and-smartphone-growth-drive-revenue-beat" target="_blank" rel="noreferrer noopener">Lenovo Q2 Earnings: Cloud Momentum, AI PCs, And Smartphone Growth Drive Revenue Beat</a></li>
</ul>
Photo by wakamatsu.h via Shutterstock

Government

News

Regulations

Tech

Media

Taiwan Semiconductor Plans Major Global Expansion, Sets Record $38 Billion Investment Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Neutral and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

ZURA

HC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) with a Buy and maintains $110 price target.

HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $110 Price Target

Chinese electric scooter company Niu Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) reported a fiscal third-quarter 2024 revenue growth of 10.5% to 1.02 billion Chinese yuan ($145.90 million), mainly due to an increase in sales volume of 17.5%, partially offset by a decrease in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42029845/niu-technologies-announces-unaudited-third-quarter-2024-financial-results" rel="noreferrer noopener">revenues per e-scooter of 6.0%</a>.
The company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">loss per ADS of&nbsp;$(0.07)</a>.&nbsp;Adjusted&nbsp;net loss was (34.25) million&nbsp;Chinese yuan, compared to&nbsp;(69.96) million Chinese yuan loss a year ago.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41986215/disneys-streaming-profits-and-park-rebound-lead-the-way-analyst" rel="noreferrer noopener">Disney&#8217;s Streaming Profits And Park Rebound Lead The Way: Analyst</a>
The number of e-scooters sold increased by 17.5%&nbsp;Y/Y&nbsp;to 312,405, with sales in China growing by 12.4%.&nbsp;International e-scooter sales climbed 50.3% to 53,311 units. The number of franchised stores in China was 3,345 as of September 30, 2024.
The quarterly gross margin declined 760 basis points Y/Y to 13.8%, mainly due to a higher proportion of kick-scooter sales in international markets, changes in the product mix of e-scooters, and increased sales incentives to franchisees in the Chinese market.
The operating loss for the quarter was (58.49) million&nbsp;Chinese yuan versus&nbsp;a loss of (89.52) million Chinese yuan a year ago.&nbsp;The&nbsp;company held 1.05 billion Chinese yuan in cash and equivalents&nbsp;as of September 30, 2024.
CEO Yan Li noted that third-quarter sales growth fell short of targets due to recent policy changes in China affecting sales timing. However, retail demand remains robust, and the upcoming product lineup aligns with the new regulations, positioning the company well to manage these shifts. The launch of the NX Hyper electric motorcycle represents a key milestone, emphasizing a focus on performance and innovation.
Li added that the company has maintained a strong pace of new store openings this year, creating a solid base for future growth. At the recent Milan EICMA event, they introduced a series of new scooters, highlighting advanced design and innovative technology. These models will soon launch in the EU and the US.
Li expressed confidence in navigating market changes and delivering strong performance.
Outlook: Niu&nbsp;expects <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">fourth-quarter&nbsp;revenues</a> of 622 million Chinese yuan &#8211; 718 million Chinese yuan, representing a&nbsp;30%-50%&nbsp;Y/Y&nbsp;increase.
Niu Technologies stock plunged 7% year-to-date.
Price Action: NIU shares closed lower by 0.50% at $1.99 on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41985546/rivian-volkswagen-deal-strengthens-finances-yet-ev-market-risks-remain-goldman-sachs" target="_blank" rel="noreferrer noopener">Rivian-Volkswagen Deal Strengthens Finances, Yet EV Market Risks Remain: Goldman Sachs</a></li>
</ul>

Earnings

Equities

Guidance

Niu Q3 Earnings: Scooter Volume Up, But Price Drops And Margins Tighten, Strong Q4 Outlook And More

Biotech

Large Cap

Health Care

General

AstraZeneca's Tagrisso (Osimertinib) Has Been Recommended For Approval In The European Union For Adult Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer With Unresectable Epidermal Growth Factor Receptor-Mutated Lung Cancer

HC Wainwright &amp; Co. analyst Scott Buck reiterates East Side Games Grp (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EAGR#TSX">EAGR</a>) with a Buy and maintains C$3 price target.

TSX:EAGR

HC Wainwright & Co. Reiterates Buy on East Side Games Grp, Maintains C$3 Price Target

Prenetics In Partnership With David Beckham, Announced The Official Launch Of IM8, A Health And Wellness Brand that Introduces Two Premium Products, Daily Ultimate Essentials, And Daily Ultimate Longevity, Both Now Available For Purchase At IM8Health.Com, With Shipping To 31 Countries, Including Free Shipping To US, UK, Canada, Singapore, And Hong Kong

HC Wainwright &amp; Co. analyst Amit Dayal maintains Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) with a Buy and lowers the price target from $18 to $5.

PLUG

HC Wainwright & Co. Maintains Buy on Plug Power, Lowers Price Target to $5

On Friday, November 15, U.S. markets closed lower, with the S&amp;P 500 and Nasdaq recording their steepest losses in two weeks. The decline was fueled by worries over delayed interest rate cuts, reactions to economic data, and Trump&#8217;s cabinet picks, including Robert F. Kennedy Jr., raising vaccine policy concerns.
Related: <a target="_blank" href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers" rel="noreferrer noopener">European And U.S. Vaccine Stocks Are Under Pressure &#8211; Here&#8217;s Why</a>
According to economic data, U.S. export prices rose by 0.8% in October, while import prices increased by 0.3%. Retail sales grew 0.4% month-over-month, exceeding market expectations of 0.3% but lower than September&#8217;s revised 0.8% gain.
Most S&amp;P 500 sectors fell, led by losses in tech, communication services, and healthcare, while utilities and financials gained, defying the broader market trend.
The Dow Jones Industrial Average was down 0.47% and closed at 43,750.86, the S&amp;P 500 declined 0.50% to 5,949.17, and the Nasdaq Composite slid 0.64% to finish at 19,107.65.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 declined 1.05% and ended the session at 38,232.50, led by losses in the Real Estate, Shipbuilding, and Financial Services sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.18% and ended the day at 8,300.20, led by gains in the Consumer Staples, Utilities and Gold sectors.</li>
<li>India&#8217;s Nifty 50 closed 0.50% lower at 23,462.70, and Nifty 500 down 0.28% at 21,901.10, led by losses in the Technology, Oil &amp; Gas, and Fast Moving Consumer Goods sectors.</li>
<li>China&#8217;s Shanghai Composite declined 0.21% to close at 3,323.85, and the Shenzhen CSI 300 fell 0.46%, finishing the day at 3,950.38.</li>
<li>Hong Kong&#8217;s Hang Seng gained 0.77% and closed the session at 19,576.61.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 0.27%.</li>
<li>Germany&#8217;s DAX slid 0.08%.</li>
<li>France&#8217;s CAC fell 0.00%.</li>
<li>FTSE 100 index traded higher by 0.30%</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.70% at $67.39/bbl, and Brent was up 0.73% at $71.56/bbl.</li>
<li>Oil prices rose amid the escalating Russia-Ukraine conflict. However, market gains were tempered by weak demand in China and a global oil surplus forecast. U.S. support for Ukrainian strikes against Russia increased geopolitical risks.</li>
<li>Natural Gas rose 2.34% to $2.888.</li>
<li>Gold was trading higher by 0.99% at $2,595.80, Silver gained 1.27% to $30.820, and Copper rose 0.46% to $4.0830.</li>
<li>Gold prices rose, supported by a slowing dollar rally. Investors await Federal Reserve comments amid strong U.S. economic data reducing expectations for December rate cuts.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures declined 0.22%, S&amp;P 500 futures up 0.02%, and Nasdaq 100 futures gained 0.35%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. dollar index gained 0.02% to 106.70, the USD/JPY rose 0.41% to 154.97, and the USD/AUD rose 0.08% to 1.5484.</li>
<li>The dollar strengthened against the yen as Bank of Japan Governor Kazuo Ueda signaled potential future rate hikes without confirming timing.</li>
</ul>
Image via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mostly Lower, Dollar's Uptrend Continues - Global Markets Today While US Slept

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) with a Buy and maintains $3 price target.

MVST

HC Wainwright & Co. Reiterates Buy on Microvast Holdings, Maintains $3 Price Target

Company also announces certification of FlashBlade//S500 with NVIDIA DGX SuperPOD for the most demanding AI data center requirements

NVDA

PSTG

Pure Storage Rolls Out GenAI Pod To Accelerate Enterprise AI Innovation, Partners With NVIDIA For Certified AI Data Center Solutions

Swvl Holdings Corp ("Swvl" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>), a leading provider of technology-driven mobility solutions for enterprises and governments, today announced its entry into a definitive agreement with certain investors, including several members of its board of directors, to purchase $4.7 million of ordinary shares (or their equivalent) in a private placement, at a purchase price of $4.79 per share (its closing price on November 15, 2024). The purchasers have agreed to lock up the securities purchased in the offering for a period of 6 months, and also to transfer less than 20 percent of the securities purchased for each 90-day period thereafter in an amount not more than 20 percent of the trading volume on the date of sale.
The private placement is expected to close on or about November 18, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes, including the expansion of its operations in the United States.

Offerings

SWVL

Swvl Announces $4.7M Private Placement To Fund U.S. Expansion Amid Investor Backing

Buybacks

SINT

SINTX Technologies Board Plans Buy Back Up To $500K Of Outstanding Common Stock Over Next Several Quarters Which Equates To About 20% Of Total Outstanding Shares

China Automotive Systems, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) ("CAAS" or the "Company"), a leading power steering components and systems supplier in China, today announced that its board of directors approved a share repurchase program of up to $5 million of its outstanding common shares periodically over the next 12 months. Repurchases will be made in open market transactions, at prevailing market prices not to exceed $5.50 per share through November 15, 2025, subject to applicable laws, regulations and approvals. The timing of the share repurchases will depend on a variety of factors, including market conditions. Members of the management team may make additional share purchases in addition to the Company repurchase.

CAAS

China Automotive Systems Board Approved A Share Buyback Program Of Upto $5M Shares Over Next 12 Months

CORRECTION: Niu Technologies Q3 Adj EPADS $(0.06) Up From $(0.14) YoY, Sales $145.90M Up From $127.06M YoY

The victory of President-elect Donald Trump accompanied by stronger-than-expected economic data has been able to shrug off the worries from the rise in Treasury yields as the S&amp;P 500 Index, which fell by 2.3% last week at 5,870.62 is still higher than its pre-election levels of 5,712.69 points on Monday, Nov. 4.
However, Fed Chair Jerome Powell&#8216;s pirouette on interest rate reduction on Thursday last week may soon start weighing in on the equity markets as experts have highlighted the possible concerns about a &#8220;tighter monetary environment&#8221; if the economy remains strong. 
After the 25 basis Nov. 7 rate cut, <a href="https://www.benzinga.com/news/treasuries/24/11/41993899/powells-hawkish-remarks-shake-markets-stocks-fall-dollar-rockets-bitcoin-dips">Powell said </a>that &#8220;the economy is not sending any signals that we need to be in a hurry to lower rates.&#8221;
What Happened: Reducing interest rates increases liquidity in the system, thus giving a boost to investment in equities, but on the contrary, holding the interest rates at a higher level causes the liquidity to reduce, yields to rise, and consequently, the economy to shrink.
While the U.S. inflation and economy shows no sign of cooling off, Fed officials may decide not to cut the rates further in their Dec. 17-18 meeting, which will impact the equity markets. 
The U.S. two-year Treasury yield rose to 4.31%, whereas the ten-year yield jumped to 4.45% on Friday. &#8220;If yields continue to trend up and they don&#8217;t find their ceiling, I think it will become a problem because it will basically translate into a tighter monetary environment,&#8221; said Irene Tunkel, chief U.S. equity strategist at BCA Research, to Reuters.
Also read: <a href="https://www.benzinga.com/news/treasuries/24/11/41993899/powells-hawkish-remarks-shake-markets-stocks-fall-dollar-rockets-bitcoin-dips">Powell&#8217;s Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips</a>
Why It Matters: &#8220;A tighter monetary environment&#8221; corresponds to higher central bank interest rates, lower bond prices, and higher yields. A tighter monetary policy, causes the yields to rise in the short term and makes borrowing more expensive, gradually reducing the liquidity in the system and hampering the growth while increasing the fear of recession.
The Federal Open Market Committee has the behemoth task of determining the rates and setting the targets while maintaining economic growth. Moreover, a tighter monetary environment is feared by equity investors as fixed-income and debt instruments become more lucrative than equities.
&#8220;Just last Thursday, at his presser, he (Powell) claimed that the FFR (Federal Fund Rate) was still too restrictive and had to be lowered to the neutral FFR. Meanwhile, our new &#8216;Nirvana Model&#8217; shows that both the unemployment rate and inflation rates suggest that the current FFR is at the neutral rate.&#8221; said Yardeni Research in one of their quick takes.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1000" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18035655/yardeni-nirvana.png" alt="" class="wp-image-652468" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18035655/yardeni-nirvana.png 1000w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18035655/yardeni-nirvana-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18035655/yardeni-nirvana-768x432.png 768w" sizes="(max-width: 1000px) 100vw, 1000px" /></figure>
Also read: <a href="https://www.benzinga.com/markets/equities/24/11/42029975/cathie-wood-redirects-elon-musks-doge-focus-toward-nuclear-energy-amid-regulatory-challenges-heres-how-oklo-cameco-centrus-energy-and-other-stocks-performed">Cathie Wood Redirects Elon Musk&#8217;s DOGE Focus Toward Nuclear Energy Amid Regulatory Challenges: Here&#8217;s How Oklo, Cameco, Centrus Energy And Other Stocks Performed</a>
Talking about the two-year and ten-year Treasuries, the note added that &#8220;we expect both yields to be range bound between 4.25% and 4.75% over the rest of this year and possibly into next year.&#8221;
Adding about equities the Yardeni Research note said that &#8220;this might be a signal that the stock market could experience a correction now that the Fed might pause rate cutting. Nevertheless, we expect a Santa Claus rally in the S&amp;P 500 to 6,100 points by the end of this year.&#8221;
Similar to the S&amp;P 500 Index, the Nasdaq Composite fell by 3.49% last week to 18,680.12 points but remains higher than its Nov. 4 level of 18,179.98 points. NYSE Composite, which was 1.46% lower last week at 19,645.77 points, is also higher than its pre-election level of 19,243.39 points. The SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which tracks the S&amp;P 500 Index has had a similar momentum in 2024.
Read next:&nbsp;<a href="https://www.benzinga.com/markets/24/11/42017638/activist-hedge-fund-valueact-boosts-meta-stake-with-121m-bet-but-ceo-morfit-supports-mark-zuckerberg" target="_blank" rel="noreferrer noopener">Activist Hedge Fund ValueAct Boosts Meta Stake With $121M Bet, But CEO Morfit Supports Mark Zuckerberg's AI Vision: Here's What Investors Should Know</a>
Image Via Shutterstock

Macro Economic Events

Treasuries

Economics

Trump Victory-Led Rally In Stocks Shrugged Off Rise In Yields, But Analyst Says If Treasuries 'Don't Find A Ceiling…It Will Become A Problem': Here's What It Means For Investors

<a href="https://www.digitimes.com/news/a20241118PD207/tsmc-donald-trump-cowos-capacity-demand.html" title="https://www.digitimes.com/news/a20241118PD207/tsmc-donald-trump-cowos-capacity-demand.html">https://www.digitimes.com/news/a20241118PD207/tsmc-donald-trump-cowos-capacity-demand.html</a>

DigiTimes Reported Earlier, TSMC Adjusts Chip-on-Wafer-on-Substrate (CoWoS) Capacity Plans Amid Trump 2.0 Uncertainty

Wolfe Research analyst Jacob Lacks downgrades Matson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) from Outperform to Peer Perform.

Downgrades

MATX

Wolfe Research Downgrades Matson to Peer Perform

Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>), a physician-led, integrated healthcare delivery system comprised of 23 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in ten states and primary care-centric, risk-bearing physician networks, today announced the opening of Milwaukee ER &amp; Hospital, located at 1751 W Layton Ave, Milwaukee, WI 53221.
The staff of medical experts at Milwaukee ER &amp; Hospital are bringing the community 24/7/365 days of concierge-level care. The 20,000 square foot state-of-the-art facility houses 8 emergency room beds, 6 inpatient beds, one procedure room, an in-house pharmacy, laboratory services, and imaging, including MRI, CT scan, X-ray, and Ultrasound.&nbsp; &nbsp;
"Our expert team of emergency physicians looks forward to showing each patient individualized, excellent care," stated Michaela Wood, M.D., Chief Medical Officer at Milwaukee ER &amp; Hospital.
Patients will be met with the convenience of emergency care in the comfort of a relaxing environment, a short wait, and ample one-on-one time with a board-certified physician. No matter the injury or illness a patient presents, Milwaukee ER &amp; Hospital is equipped to treat patients efficiently and effectively.
Following the opening of Green Bay ER &amp; Hospital in Green Bay, Wisconsin and Post Falls ER &amp; Hospital in Post Falls, Idaho, this is the Company's third opening of 2024,
"We are excited to provide concierge level medical care to the south Milwaukee market, which historically has been underserved," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

NUTX

Nutex Health Opens State-of-the-Art ER in Milwaukee, Offering Comprehensive Emergency Services

Corpay, Inc.&#x2A;, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) a global leader in corporate payments, is pleased to announce that Corpay's Cross-Border business has entered into a multi-year agreement to extend their successful collaboration with World Aquatics as their Official FX Payments Supplier.
Corpay Cross-Border has provided a range of corporate foreign exchange payments solutions for World Aquatics, the global governing body of six aquatic disciplines – Swimming, Water Polo, Diving, High Diving, Artistic Swimming and Open Water Swimming since 2022. Under this multi-year extension, World Aquatics, along with the global aquatics' community, event hosts and World Aquatics partners will continue to benefit from access to Corpay Cross-Border's innovative global payments and currency risk management solutions.

CPAY

Corpay Extends Partnership With World Aquatics, Continues As Official FX Payments Supplier

TD Cowen analyst Marc Frahm has maintained their bullish stance on KYMR stock, giving a Buy rating on October 24. Marc Frahm has given his Buy rati...

Kymera Therapeutics: Strategic Focus and Promising Trials Justify Buy Rating

Kymera Therapeutics, Inc. ( ($KYMR) ) has released its Q3 earnings. Here is a breakdown of the information Kymera Therapeutics, Inc. presented to i...

Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price ...

Kymera Therapeutics: Promising Immunology Pipeline and Strategic Focus on KT-621 and KT-474 Programs

U.S. drugmakers and biotechs rely on Chinese partners for manufacturing, research, and ingredients, but, with geopolitical tensions rising, compani...

U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a pri...

Stifel Nicolaus Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price targe...

Oppenheimer Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Guggenheim raised the firm's price target on Kymera Therapeutics (KYMR) to $52 from $45 and keeps a Buy rating on the shares. The firm is updating ...

Kymera Therapeutics price target raised to $52 from $45 at Guggenheim

Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript

Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV – Research Report), Halozyme (HALO – Research...

Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report),...

Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)

ALNY

AZNCF

FOLD

HALO

IVVD

KYMR

Financing

Press Releases

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

Comments

Kymera Therapeutics

Intérêt court

Kymera Therapeutics (NASDAQ:KYMR) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL